|
Flexibility Urged for FDA-Approved Drugs Launching in Developing Nations
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered FDA-approved products before testing for quality issues, according to a new study.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives